CareDx: A Focused Transplant Diagnostics Compounder — Buy into the Re-rate
CareDx is sharpening into a higher-margin transplant diagnostics leader. A $170M sale of its Lab Products business and a strong preliminary Q1 2026 update (revenue +39% YoY; Testing Services +48%) create a realistic mid-term trade: buy at current levels with a $38 target and a $24 stop. The company is cash-flow positive and trading at a market cap …